Premium
Biological disease‐modifying drugs for rheumatoid arthritis
Author(s) -
Chaplin Steve
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1836
Subject(s) - medicine , rheumatoid arthritis , antirheumatic drugs , biological drugs , adverse effect , disease , monoclonal antibody , antirheumatic agents , intensive care medicine , pharmacology , immunology , antibody
There are now nine biological disease‐modifying antirheumatic drugs (bDMARDs) available for the treatment of rheumatoid arthritis – seven monoclonal antibodies and two fusion proteins. This article summarises their indications, efficacy, place in therapy and adverse effects.